Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update
- 1 December 2017
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 98 (12), 2895-2911
- https://doi.org/10.1099/jgv.0.000980
Abstract
Oncolytic virus (OV) therapy is an anti-cancer approach that uses viruses that preferentially infect, replicate in and kill cancer cells. Vesicular stomatitis virus (VSV, a rhabdovirus) is an OV that is currently being tested in the USA in several phase I clinical trials against different malignancies. Several factors make VSV a promising OV: lack of pre-existing human immunity against VSV, a small and easy to manipulate genome, cytoplasmic replication without risk of host cell transformation, independence of cell cycle and rapid growth to high titres in a broad range of cell lines facilitating large-scale virus production. While significant advances have been made in VSV-based OV therapy, room for improvement remains. Here we review recent studies (published in the last 5 years) that address ‘old’ and ‘new’ challenges of VSV-based OV therapy. These studies focused on improving VSV safety, oncoselectivity and oncotoxicity; breaking resistance of some cancers to VSV; preventing premature clearance of VSV; and stimulating tumour-specific immunity. Many of these approaches were based on combining VSV with other therapeutics. This review also discusses another rhabdovirus closely related to VSV, Maraba virus, which is currently being tested in Canada in phase I/II clinical trials.Keywords
This publication has 134 references indexed in Scilit:
- Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunityBlood Cancer Journal, 2013
- Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-βCancer Gene Therapy, 2012
- Curative one-shot systemic virotherapy in murine myelomaLeukemia, 2012
- Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapyJournal of Molecular Medicine, 2012
- VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic LeukemiaMolecular Therapy, 2010
- Identification of Genetically Modified Maraba Virus as an Oncolytic RhabdovirusMolecular Therapy, 2010
- Synergistic Interaction Between Oncolytic Viruses Augments Tumor KillingMolecular Therapy, 2010
- Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman PrimatesHuman Gene Therapy, 2010
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisProceedings of the National Academy of Sciences of the United States of America, 2008
- Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesVirology, 2007